| |
| | Kosan's Chief Executive Officer Resigns |
 | | Robert Johnson Appointed Acting CEO HAYWARD, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Daniel V. Santi, M.D., Ph.D., has resigned as Chief Executive Officer and Chairman of the Board of Directors of the company. |
 | | Robert G. Johnson, Jr., M.D., Ph.D., Kosan's current Executive Vice President, Development and Chief Medical Officer, will serve as acting CEO on an interim basis until a permanent CEO is appointed by the Board of Directors. |
 | | Therefore, it is an appropriate time for a new CEO to lead Kosan in its next phase of growth." "Dan has done a terrific job in transitioning Kosan from an early stage polyketide technology company to one with a diverse development pipeline," said Peter Davis, lead independent director of Kosan's Board of Directors. |
| www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-14-2006/0004282281&EDATE= (656 words) |
|